Fineline Cube

Follow:
14409 Articles
Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer
CompanyDrug

Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer

Innovent Doses First Patient in Phase 1 Trial of IBI3011, China’s First Anti‑IL‑1RAP Antibody for Gout Flares
CompanyDrug

Innovent Doses First Patient in Phase 1 Trial of IBI3011, China’s First Anti‑IL‑1RAP Antibody for Gout Flares

Shanghai Henlius Secures NMPA Approval for Phase II/III HLX22 HER2 Trials, Pioneering Novel Epitope ADC Combination in Breast Cancer
CompanyDrug

Shanghai Henlius Secures NMPA Approval for Phase II/III HLX22 HER2 Trials, Pioneering Novel Epitope ADC Combination in Breast Cancer

Shandong Boan Licenses US Rights for Denosumab Biosimilars to Nanjing Kingfriend in $75 Million Deal
CompanyDeals

Shandong Boan Licenses US Rights for Denosumab Biosimilars to Nanjing Kingfriend in $75 Million Deal

FDA Waskyra WAS Gene Therapy First Cell-Based
CompanyDrug

FDA Waskyra WAS Gene Therapy First Cell-Based

FDA Omisirge Severe Aplastic Anemia First HSCT
CompanyDrug

FDA Omisirge Severe Aplastic Anemia First HSCT

Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development
CompanyDeals

Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development

Lee's Pharm Staccato-OBT Acquisition Bolsters UCB Partnership
CompanyDeals

Lee’s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership

Zhaoke BRIMOCHOL-PF Taiwan License Targets Presbyopia Market
CompanyDeals

Zhaoke BRIMOCHOL-PF Taiwan License Targets Presbyopia Market

Kexing GB10 nAMD Injection Secures NMPA Clinical Trial Approval
CompanyDrug

Kexing GB10 nAMD Injection Secures NMPA Clinical Trial Approval

Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy
CompanyDrug

Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy

Ignis Therapeutics Solriamfetol NMPA Approval Targets OSA Sleepiness
CompanyDrug

Ignis Therapeutics Solriamfetol NMPA Approval Targets OSA Sleepiness